XIGDUO Extended Release (XR) (DAPAGLIFLOZIN/METFORMIN XR FDC) Regulatory Postmarketing Surveillance To Observe Safety and Effectiveness Of XigduoXR (Registered) In Korean Patients
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Dapagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms XigduoPMS
- Sponsors AstraZeneca
- 22 May 2017 Planned End Date changed from 1 Jun 2019 to 31 Dec 2018.
- 22 May 2017 Planned primary completion date changed from 1 Jun 2019 to 31 Dec 2018.
- 22 May 2017 Status changed from not yet recruiting to recruiting.